Stryker Corporation
SYKHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeStryker Corporation operates as a medical technology company in the United States and internationally. At a $117.81B market cap, Stryker Corporation ranks as a large-cap company within healthcare. It operates through two segments, MedSurg and Neurotechnology, and Orthopaedics.
Market Cap
$117.81B
Beta
0.78
P/E (TTM)
31.83
P/E (Fwd)
18.43
EPS (TTM)
$9.65
EPS (Fwd)
$16.66
ROE
16.5%
ROA
8.2%
Cash
$3.48B
Total Debt
$15.45B
Free CF
$4.11B
52W Change
-20.0%
Annual Financials
Cash vs Debt
Where SYK stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, SYK finished 6.28% below its 150-day moving average ($312.87) and 9.80% below its 200-day moving average ($325.10). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is SYK overbought or oversold?
At the October 16, 2026 close, SYK's RSI(14) was 70.4, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, SYK has $3.48B in cash with $15.45B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $4.11B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 16.5%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 8.2% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $18.45B (2022) to $25.12B (2025), reflecting a 36% increase over the period.
As with any equity investment, SYK carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Stryker Corporation's trajectory.